These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27200481)

  • 1. Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.
    Joseph DA; Meester RG; Zauber AG; Manninen DL; Winges L; Dong FB; Peaker B; van Ballegooijen M
    Cancer; 2016 Aug; 122(16):2479-86. PubMed ID: 27200481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening.
    Grobbee EJ; Kapidzic A; van Vuuren AJ; van Leerdam M; Lansdorp-Vogelaar I; Looman CW; Bruno MJ; Kuipers EJ; Spaander MC
    Am J Gastroenterol; 2015 Jul; 110(7):1072-7. PubMed ID: 26054624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.
    Meester RG; Zauber AG; Doubeni CA; Jensen CD; Quinn VP; Helfand M; Dominitz JA; Levin TR; Corley DA; Lansdorp-Vogelaar I
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1445-1451.e8. PubMed ID: 27211498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States?
    Seeff LC; Manninen DL; Dong FB; Chattopadhyay SK; Nadel MR; Tangka FK; Molinari NA
    Gastroenterology; 2004 Dec; 127(6):1661-9. PubMed ID: 15578502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
    Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study.
    Zhu M; Zhong X; Liao T; Peng X; Lei L; Peng J; Cao Y
    BMC Public Health; 2024 Mar; 24(1):655. PubMed ID: 38429684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colonoscopy Needs for Implementation of a Colorectal Cancer Screening Program in Ukraine.
    Welten VM; Wanis KN; Semeniv S; Shabat G; Dabekaussen KFAA; Davids JS; Beznosenko A; Suprun U; Soeteman DI; Melnitchouk N
    World J Surg; 2022 Oct; 46(10):2476-2486. PubMed ID: 35835863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.
    Meester RGS; Peterse EFP; Knudsen AB; de Weerdt AC; Chen JC; Lietz AP; Dwyer A; Ahnen DJ; Siegel RL; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2974-2985. PubMed ID: 29846942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Prediction of the Demand of Colonoscopies Generated by a Population-Based Colorectal Cancer Screening Program.
    Comas M; Mendivil J; Andreu M; Hernández C; Castells X
    PLoS One; 2016; 11(10):e0164666. PubMed ID: 27732635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
    Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
    PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario.
    Lau A; Gregor JC
    Can J Gastroenterol; 2007 Jun; 21(6):371-7. PubMed ID: 17571171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.